Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma
Autor: | Lauren B. Smith, Mark S. Kaminski, Anca M. Avram, Scott J. Wilderman, Yuni K. Dewaraja, Peter L. Roberson, Meredith A. Morgan, Matthew J. Schipper |
---|---|
Rok vydání: | 2017 |
Předmět: |
Adult
Male Patient-Specific Modeling Cancer Research medicine.medical_treatment Disease-Free Survival 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine immune system diseases hemic and lymphatic diseases Dose prediction Biomarkers Tumor medicine Humans Dosimetry Radiology Nuclear Medicine and imaging Radiosensitivity Aged Aged 80 and over Tomography Emission-Computed Single-Photon Pharmacology medicine.diagnostic_test business.industry Lymphoma Non-Hodgkin Radiotherapy Planning Computer-Assisted Dose-Response Relationship Radiation Radiotherapy Dosage Original Articles General Medicine Middle Aged Radioimmunotherapy medicine.disease Lymphoma Treatment Outcome Oncology Positron emission tomography 030220 oncology & carcinogenesis Biomarker (medicine) Female Tomography X-Ray Computed Nuclear medicine business Emission computed tomography |
Zdroj: | Cancer Biotherapy and Radiopharmaceuticals. 32:309-319 |
ISSN: | 1557-8852 1084-9785 |
Popis: | Non-Hodgkin Lymphoma patients respond differently to therapy according to inherent biological variations. Pretherapy biomarkers may improve dose-response prediction.Hybrid single-photon emission computed tomography (SPECT)/computed tomography (CT) three-dimensional imaging at multiple time points plus follow-up positron emission tomography (PET)/CT or CT at 2 and 6 months post therapy were used to fit tumor response to combined biological effect and cell clearance models from which three biological effect response parameters (radiosensitivity, cold effect sensitivity, and proliferation potential) were determined per patient. A correlation of biological effect parameters and pretherapy biomarker data (ki67, p53, and phospho-histone H3) allowed a dose-based equivalent biological effect (EBE) to be calculated for each patient.Significant correlations were found between biological effect parameters and pretherapy biomarkers. Optimum correlations were found by splitting the patient data according to p53 status. Response correlation of progression free survival (PFS) and EBE were significantly improved compared with PFS and absorbed dose alone.It is possible and desirable to use pretherapy biomarkers to enhance the predictive potential of dose calculations for patient-specific treatment planning. |
Databáze: | OpenAIRE |
Externí odkaz: |